Table 2.
Main characteristics of study participants, by treatment and control group. Number (N), column percentage (%) and p-value (chi-square test).
| Variables | Categories | Treated (N = 50) N (%) |
Controls (N = 58) N (%) |
p-Value | |
|---|---|---|---|---|---|
| Sex | Female | 30 (60.0) | 35 (60.3) | 0.971 | |
| Male | 20 (40.0) | 23 (39.7) | |||
| Age (years) | <40 | 19 (42.2) | 22 (38.6) | 0.933 | |
| 40–59 | 20 (44.4) | 27 (47.4) | |||
| 60+ | 6 (13.3) | 8 (14.0) | |||
|
Smoking
status |
Non-smoker | 36 (72.0) | 42 (72.4) | 0.530 | |
| Ex-smoker | 9 (18.0) | 7 (12.1) | |||
| Current smoker | 5 (10.0) | 9 (15.5) | |||
|
Alcohol
consumption |
Non-drinker | 20 (40.0) | 19 (32.8) | 0.285 | |
| Occasional drinker | 29 (58.0) | 34 (58.6) | |||
| Regular drinker | 1 (2.0) | 5 (8.6) | |||
| Number of doses of COVID-19 vaccines | 0 | 5 (10.0) | 1 (1.7) | 0.148 | |
| 1 | 1 (2.0) | 0 | |||
| 2 | 5 (10.0) | 4 (6.9) | |||
| 3 | 39 (78.0) | 53 (91.4) | |||
| Vaccine type |
1st
dose |
Comirnaty | 36 (80.0) | 47 (82.5) | 0.480 |
| Spikevax | 6 (13.3) | 4 (7.0) | |||
| Vaxzevria | 3 (6.7) | 6 (10.5) | |||
|
2nd
dose |
Comirnaty | 35 (80.0) | 47 (82.5) | 0.710 | |
| Spikevax | 6 (13.6) | 5 (8.8) | |||
| Vaxzevria | 3 (6.8) | 5 (8.8) | |||
|
3rd
dose |
Comirnaty | 18 (46.2) | 19 (36.5) | 0.355 | |
| Spikevax | 21 (53.9) | 33 (63.5) | |||
| Vaxzevria | 0 | 0 | |||
|
Hypertension
(missing: 6) |
No | 37 (82.2) | 47 (82.5) | 0.975 | |
| Yes | 8 (17.8) | 10 (17.5) | |||
| Diabetes | No | 49 (98.0) | 57 (98.3) | 0.916 | |
| Yes | 1 (1.8) | 1 (1.7) | |||
|
Cardiovascular
diseases |
No | 50 (100) | 58 (100) | NA | |
| Yes | 0 | 0 | |||
| Cerebrovascular diseases | No | 49 (98.0) | 58 (100) | 0.279 | |
| Yes | 1 (1.8) | 0 | |||
| Cancer | No | 47 (94.0) | 54 (93.1) | 0.850 | |
| Yes | 3 (5.3) | 4 (6.9) | |||
| COPD | No | 42 (84.0) | 52 (89.7) | 0.383 | |
| Yes | 8 (14.0) | 6 (10.3) | |||
| Renal disease | No | 50 (100) | 57 (98.3) | 0.351 | |
| Yes | 0 | 1 (1.7) | |||